Related Experiment Video
Updated: Feb 20, 2026
Multiplexed Fluorescent Immunohistochemical Staining, Imaging, and Analysis in Histological Samples of Lymphoma
Published on: January 9, 2019
Immunohistochemical Expression of CD10, BCL6 and MUM1 in Differentiating Diffuse Large B Cell Lymphoma Subtypes
Akhter Ali Bajwa1, Muhammad Tahir Khadim1, Hafeez Ud Din2
1Department of Pathology, Combined Military Hospital, Multan.
Insights
Immunohistochemical markers CD10, BCL6, and MUM1 help differentiate diffuse large B cell lymphoma (DLBCL) subtypes. The Pakistani population shows a high frequency of the non-GCB type, indicating a potential high-risk subset.
Area of Science:
- Hematopathology
- Oncology
- Immunohistochemistry
Background:
- Diffuse large B cell lymphoma (DLBCL) is a heterogeneous group of lymphoid malignancies.
- Accurate subtyping of DLBCL is crucial for prognostication and treatment selection.
- Immunohistochemistry (IHC) plays a vital role in classifying DLBCL subtypes.
Purpose of the Study:
- To investigate the expression patterns of CD10, BCL6, and MUM1 in differentiating DLBCL subtypes.
- To assess the utility of these markers in classifying Germinal Center B-cell (GCB) and non-GCB (activated) DLBCL.
- To evaluate the frequency of these subtypes in a Pakistani population.
Main Methods:
- A descriptive, cross-sectional study was conducted on 96 newly diagnosed DLBCL cases.
- Immunohistochemical staining for CD10, BCL6, and MUM1 was performed.
- DLBCL subtypes (GCB and non-GCB) were determined based on marker expression, and data were analyzed using SPSS.
Main Results:
- Out of 96 patients, 37.5% were classified as GCB type (CD10+/BCL6+) and 62.5% as non-GCB type (MUM1+).
- A statistically significant association was observed between the expression of CD10, BCL6, and MUM1 and DLBCL subtypes (p<0.001).
- The study found a higher prevalence of the non-GCB type (62.5%) in the Pakistani population.
Conclusions:
- The expression profile of CD10, BCL6, and MUM1 effectively differentiates DLBCL subtypes.
- The high frequency of the non-GCB type in Pakistan suggests a distinct epidemiological characteristic.
- This high-risk subset warrants further investigation for tailored diagnostic and management strategies.
Objective:
To determine the immunohistochemical expression of CD10, BCL6 and MUM1 in differentiating diffuse large B cell lymphoma subtypes.
Study Design:
Descriptive, cross-sectional study.
Place And Duration Of Study:
Department of Histopathology, Armed Forces Institute of Pathology, Rawalpindi, from November 2014 to May 2015.
Methodology:
Newly diagnosed cases of DLBCLon H&E stain as well as IHC markers, according to WHO blue book 2008, were included in the study. Patients' gender, age and site of lymphoma were noted. DLBCLsubtypes (GCB and activated type or non-GCB) were assessed based on IHC expression of CD10, BCL6 and MUM1 and the results were recorded. The data were analyzed by using computer software program SPSS version 20. Descriptive statistics, frequencies and percentages were calculated.
Results:
Out of 96 patients, 79 (82%) were male and 17 (18%) were female. Mean age was 54.66 ±16.73 years. Thirty-six (37.5%) cases showed positivity for CD10 and BCL6 both (GCB type), whereas MUM1 was positive in 60 (62.5%) cases (non-GCB type or activated type). Asignificant statistical association was seen between expression of IHC markers (CD10, BCL6 and MUM1) and DLBCLsubtypes (GCB and non-GCB type, p<0.001).
Conclusion:
In Pakistani population, the frequency of non-GCB type expressing MUM1 is 62.5%, which is quite high as compared to western countries. It needs to be further explored, because it represents high-risk subsets in which alternative strategies for diagnosis and management should be planned.
